Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration by Thompson Zhuang et al.
Zhuang et al. BMC Cancer 2013, 13:590
http://www.biomedcentral.com/1471-2407/13/590RESEARCH ARTICLE Open AccessInvolvement of nitric oxide synthase in matrix
metalloproteinase-9- and/or urokinase
plasminogen activator receptor-mediated glioma
cell migration
Thompson Zhuang1, Bharath Chelluboina1, Shivani Ponnala1, Kiran Kumar Velpula1, Azeem A Rehman1,
Chandramu Chetty1, Eleonora Zakharian1, Jasti S Rao1,2 and Krishna Kumar Veeravalli1*Abstract
Background: Src tyrosine kinase activates inducible nitric oxide synthase (iNOS) and, in turn, nitric oxide production
as a means to transduce cell migration. Src tyrosine kinase plays a key proximal role to control α9β1 signaling. Our
recent studies have clearly demonstrated the role of α9β1 integrin in matrix metalloproteinase-9 (MMP-9) and/or
urokinase plasminogen activator receptor (uPAR)-mediated glioma cell migration. In the present study, we evaluated
the involvement of α9β1 integrin-iNOS pathway in MMP-9- and/or uPAR-mediated glioma cell migration.
Methods: MMP-9 and uPAR shRNAs and overexpressing plasmids were used to downregulate and upregulate
these molecules, respectively in U251 glioma cells and 5310 glioma xenograft cells. The effect of treatments on
migration and invasion potential of these glioma cells were assessed by spheroid migration, wound healing, and
Matrigel invasion assays. In order to attain the other objectives we also performed immunocytochemical,
immunohistochemical, RT-PCR, Western blot and fluorescence-activated cell sorting (FACS) analysis.
Results: Immunohistochemical analysis revealed the prominent association of iNOS with glioblastoma
multiforme (GBM). Immunofluorescence analysis showed prominent expression of iNOS in glioma cells. MMP-9
and/or uPAR knockdown by respective shRNAs reduced iNOS expression in these glioma cells. RT-PCR analysis
revealed elevated iNOS mRNA expression in either MMP-9 or uPAR overexpressed glioma cells. The migration
potential of MMP-9- and/or uPAR-overexpressed U251 glioma cells was significantly inhibited after treatment
with L-NAME, an inhibitor of iNOS. Similarly, a significant inhibition of the invasion potential of the control or
MMP-9/uPAR-overexpressed glioma cells was noticed after L-NAME treatment. A prominent reduction of iNOS
expression was observed in the tumor regions of nude mice brains, which were injected with 5310 glioma cells,
after MMP-9 and/or uPAR knockdown. Protein expressions of cSrc, phosphoSrc and p130Cas were reduced with
simultaneous knockdown of both MMP-9 and uPAR.
Conclusions: Taken together, our results from the present and earlier studies clearly demonstrate that α9β1
integrin-mediated cell migration utilizes the iNOS pathway, and inhibition of the migratory potential of glioma
cells by simultaneous knockdown of MMP-9 and uPAR could be attributed to the reduced α9β1 integrin and
iNOS levels.
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High grade gliomas invariably recur due in a large part to
tumor cells penetrating the normal brain in an inaccess-
ible, diffuse manner. Further, the tendency of glioblastoma
multiforme (GBM) cells to migrate and invade normal
brain tissue renders surgical interventions ineffective [1].
Glioma cell migration and invasion is generally separated
into three phases. First, the glioma cells attach to proteins
located in the extracellular matrix (ECM) with the aid of
cell adhesion receptors. Subsequently, ECM proteins are
degraded by proteases secreted by the glioma cells, such
as MMPs and serine proteases. ECM degradation provides
opportunity for active glioma cell migration through the
intercellular space. In human glioma cells, MMP-9 and
uPAR have been found to be overexpressed. MMP-9 has
been implicated in ECM degradation, angiogenesis, and
subsequent tumor growth and invasion [2,3]. A strong re-
lationship exists between MMP-9 levels and cell migra-
tory/invasive potential due to the crucial role of MMPs in
proteolysis of the ECM. Of the MMPs, MMP-9 was found
to be most closely linked to tumor grade [4-7]. In addition
to MMPs, the serine protease uPA has been established to
be active in the degradation of the ECM. The binding of
uPA to uPAR is essential both in vitro and in vivo for can-
cer cell metastasis, invasion, and migration. Inhibition of
uPAR prevented cancer cell metastasis. Elevated levels of
both uPA and uPAR were observed in human carcinoma
cells, elucidating uPAR’s critical role in cancer cell migra-
tion. Silencing MMP-9 and/or uPAR decreased cell adhe-
sion to ECM proteins—a process known to promote
tumor cell migration and invasion [8]. MMP-9 and/or
uPAR gene silencing also reduced invasive/migratory po-
tential and growth of glioma cells [8]. Our recent studies
clearly demonstrated the involvement of α9β1 integrin in
MMP-9-/uPAR-mediated glioma cell migration [9]. Integ-
rin α9β1 regulates inducible nitric oxide synthase (iNOS)
activity via Src tyrosine kinase; Src coordinates subsequent
signaling pathways through activation of FAK and tyrosine
phosphorylation of the adaptor protein p130Cas [10].
Inducible nitric oxide synthase and nitric oxide (NO)
are closely linked to tumor growth, proliferation, and
poor prognosis in humans with malignant glioma. NO is
a heme co-factor that activates soluble guanylyl cyclase
(GC) to produce cGMP, which regulates cell migration
in both a protein kinase G (PKG) dependent and inde-
pendent fashion [11,12]. NO, derived from tumor iNOS,
is an important modulator of tumor progression and
angiogenesis in C6 glioma cells [13]. Tumor-derived NO
may also promote invasiveness through the induction of
MMP-9 expression by tumor cells. Tumors with MMP-9
overexpression had significantly higher iNOS activity
and cGMP levels compared with tumors that had absent
or focal expression of MMP-9 in head and neck squa-
mous cell carcinoma [14]. Recently, it was reported thatα9β1 integrin regulates iNOS activity, which resulted in in-
creased NO production and NO-induced cell migration
[10]. Because α9β1 integrin plays a crucial role in MMP-9
and uPAR-mediated cell migration in glioma, we hypothe-
sized that MMP-9 and uPAR utilize iNOS via α9β1 integrin
to arbitrate cell migration. In the present study, we investi-
gated the involvement of the α9β1 integrin-iNOS pathway
in MMP-9- and/or uPAR- mediated glioma cell migration.
Methods
Ethics statement
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria, Peoria,
IL approved all surgical interventions and post-operative
animal care.
Chemicals and reagents
L-NG-Nitroarginine methyl ester (L-NAME) was obtained
from Sigma (St. Louis, MO). Recombinant human uPAR
was obtained from R&D Systems (Minneapolis, MN). Anti-
α9β1 integrin, anti-NOS2, anti-cSRC and anti-p130Cas
antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-phosphoSRC (Tyr 416) antibody
was obtained from Cell Signaling (Boston, MA). Anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body was obtained from Novus Biologicals (Littleton, CO).
Diaminofluorescein-2 Diacetate (DAF-2DA) was obtained
from Enzo Life Sciences (Farmingdale, NY).
Construction of shRNA- and gene-expressing plasmids
Plasmid shRNAs for MMP-9 (M-sh), uPAR (U-sh) and
MMP-9-uPAR (MU-sh) were designed in our laboratory
[15] and used to transfect the cells. Briefly, a pCDNA-3
plasmid with a human cytomegalovirus (CMV) promoter
was used to construct the shRNA-expressing vectors. A
pCDNA3-scrambled vector with an imperfect sequence,
which does not form a perfect hairpin structure, was used
as a control (SV-sh). MMP-9 human cDNA cloned in
pDNR-CMV vector in our laboratory was used for full-
length MMP-9 (M-fl) overexpression. We used uPAR
human cDNA cloned in pCMV6-AC vector (Origene,
Rockville, MD) for full-length uPAR (U-fl) overexpression.
Cell culture and transfection conditions
U251 human glioma cells obtained from the National
Cancer Institute (NCI) (Frederick, MD) were grown in
DMEM supplemented with 10% fetal bovine serum (FBS)
(Hyclone, Logan, UT) and 1% penicillin/streptomycin
(Invitrogen, Carlsbad, CA). 5310 human glioma xenograft
cells were kindly provided by Dr. David James at the
University of California, San Francisco. These xenografts
were generated and maintained in mice and are highly in-
vasive in the mouse brain [16]. 5310 xenografts were
maintained in RPMI 1640 supplemented with 10% fetal
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humidified atmosphere containing 5% CO2. U251 and
5310 cells were transfected with SV-sh, M-sh, U-sh, MU-
sh, M-fl, or U-fl using Fugene® HD reagent obtained from
Roche Diagnostics, (Indianapolis, IN) according to the
manufacturer’s instructions.
Wound healing assay
To study cell migration, we seeded U251 glioma cells at a
density of 1.5 × 106 or 2 × 106 in a 6-well plate and trans-
fected the cells with M-fl, or U-fl for 72 hrs. Then, a
straight scratch was made in individual wells with a 200 μl
pipette tip. This point was considered the “0 hr,” time point
and the width of the wound was photographed under the
microscope. Again at the 21st hr, the cells were checked for
wound healing and photographed under the microscope.
Wound healing was measured by calculating the reduction
in the width of the wound after incubation. The involve-
ment of the iNOS pathway on M-fl- or U-fl-mediated gli-
oma cell migration was assessed by adding L-NAME
(1 mM final concentration) at “0 hr” to the appropriate
wells containing glioma cells transfected with M-fl, or U-fl.
Spheroid migration assay
U251 glioma cells were cultured in 96-well plates coated
with 1% agar. Briefly, 3 × 104 cells/well were seeded and
cultured on a shaker at 100 rpm for 48 hr in a humidified
atmosphere containing 5% CO2 at 37°C. After the forma-
tion of spheroids, they were transfected with M-fl or U-fl
overexpressing plasmids. 48 hr after transfection, the
spheroids were transferred to 24-well plates at a density of
one spheroid/well and incubated at 37°C. At this time
point, a few spheroids from each group were treated with
L-NAME at a final concentration of 1 mM. Twenty-four
hours after incubation, the spheroids were fixed and
stained with Hema-3. Cell migration from the spheroids
was assessed using light microscopy. The migration of
cells from spheroids to monolayers was used as an index
of cell migration and was measured using a microscope
calibrated with a stage and ocular micrometer.
Matrigel invasion assay
U251 and 5310 glioma cells were transfected with M-fl or
U-fl for 72 hr. Cells were trypsinized and 5 × 104 cells
were placed onto Matrigel-coated transwell inserts of 8-
mm pore size. A few of the transwells containing un-
treated and M-fl- or U-fl-transfected glioma cells were
then subjected to L-NAME (1 mM) treatment. Cells were
allowed to migrate through the Matrigel for 24 to 48 hr.
Then, cells in the upper chamber were removed with a
cotton swab. The cells that adhered on the outer surface
of the transwell insert and had invaded through the matri-
gel were fixed, stained with Hema-3, and counted under a
light microscope as described earlier (Veeravalli et al., [8]).Intracranial administrations in nude mice
5310 glioma xenograft cells were trypsinized and re-
suspended in serum-free medium at a concentration of
0.2 × 105 cells/μL. Nude mice were injected intracerebrally
with 10 μL aliquot (0.2 × 105 cells/μL) under isofluorane
anesthesia with the aid of a stereotactic frame. After two
weeks, mice were separated into four groups. The first
group served as control. The second, third, and fourth
groups served as M-sh-treated (150 μg), U-sh-treated
(150 μg), and MU-sh-treated (150 μg) groups, respectively.
M-sh, U-sh and MU-sh plasmid DNAs were injected into
the brains of nude mice using Alzet mini pumps at the
rate of 0.2 μL/hr. The concentration of the plasmid solu-
tion was 2 μg/μL (100 μl per mouse, six mice in each
group). After 5 weeks, the mice were sacrificed by intra-
cardiac perfusion, first with PBS and then with 4% parafor-
maldehyde in normal saline. The brains were removed,
stored in 4% paraformaldehyde, processed, embedded in
paraffin, and sectioned (5 μm thick) using a microtome.
Paraffin-embedded sections were processed for immuno-
histochemical analysis.
Immunohistochemical analysis
Paraffin-embedded brain sections (5 μm thick) from con-
trol and treatment groups were de-paraffinized following
standard protocol. The sections were rinsed with PBS and
treated with 1% BSA in PBS to prevent non-specific stain-
ing and incubated with anti-iNOS antibody (1:100 dilu-
tion) at 4°C overnight. The sections were then washed in
PBS and incubated with the appropriate HRP-conjugated
secondary antibody for 1 hr at room temperature. After
1 hr, the sections were washed in PBS and incubated in
DAB for 30 min. The slides were further washed with ster-
ile water, stained with hematoxylin and dehydrated. The
slides were then covered with glass cover slips and photo-
micrographs were obtained. Immunohistochemical ana-
lysis for iNOS protein expression was also performed on
the slide tissue microarrays (obtained from US Biomax,
Inc., Rockville, MD) of clinical GBM samples according to
the manufacturer’s instructions.
Immunocytochemical analysis
U251 and 5310 cells (1 × 104) were seeded on 2-well cham-
ber slides, incubated for 24 h, and transfected with SV-sh,
M-sh, U-sh, or MU-sh for 72 hrs. Then, cells were fixed
with 10% buffered formalin phosphate and incubated with
1% bovine serum albumin in PBS at room temperature for
1 hr to avoid non-specific staining. After the slides were
washed with PBS, anti-iNOS antibody was added at a con-
centration of 1:100. The slides were incubated overnight at
4°C and washed three times with PBS to remove excess
primary antibody. Cells were then incubated with Alexa
Fluor® 594 (goat anti-mouse IgG, red) fluorescent-labeled
secondary antibody for 1 hr at room temperature. The
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posed to DAPI containing mounting media, covered with
glass coverslips, and fluorescent photomicrographs were
obtained.
Reverse transcription PCR analysis
Total cell RNA was isolated from untreated U251 and
5310 glioma cells and from those transfected with M-fl,
or U-fl. Approximately 1 μg of total RNA from each
sample was synthesized into cDNA following the manu-
facturer’s instructions using the Transcriptor First Strand
cDNA Synthesis Kit obtained from Roche Diagnostics
(Indianapolis, IN). We used the following sequences for
the forward and reverse primers:
 for iNOS, 5′cgqiztgtggaagcggtaacaaagga3′ (forward)
and 5′tgccattgttggtggagtaa3′ (reverse);
 for βActin, 5′ggcatcctcaccctgaagta3′ (forward) and
5′ggggtgttgaaggtctcaaa3′ (reverse).
Reverse transcription - polymerase chain reaction (RT-
PCR) was set up using the following PCR cycle: 95°C for
5 min, (95°C for 30 sec, 55–60°C for 30 sec, and 72°C for
30 sec) × 35 cycles, and 72°C for 10 min. PCR products
were resolved on a 1.6% agarose gel, visualized, and photo-
graphed under UV light.
Western blot analysis
U251 and 5310 cells were transfected with SV-sh, M-sh,
U-sh, M-fl and U-fl for 72 hrs. Cells were collected and
lysed in RIPA buffer [50 mmol/mL Tris–HCl (pH 8.0),
150 mmol/mL NaCl, 1% IGEPAL, 0.5% sodium deoxycho-
late, 0.1% SDS] containing 1 mM sodium orthovanadate,
0.5 mM PMSF, 10 μg/mL aprotinin, 10 μg/mL leupeptin
and resolved via SDS-PAGE. After overnight transfer onto
nitrocellulose membranes, blots were blocked with 5%
non-fat dry milk in PBS and 0.1% Tween-20. Blots were
then incubated with primary antibody, followed by incuba-
tion with HRP-conjugated secondary antibody. Immunore-
active bands were visualized using chemiluminescence ECL
Western blotting detection reagents on Hyperfilm-MP
autoradiography film obtained from Amersham (Piscat-
away, NJ). GAPDH (housekeeping gene) antibody was used
to verify that similar amounts of protein were loaded in all
lanes.
FACS analysis
U251 and 5310 cells were seeded on 100-mm tissue cul-
ture plates. Cells were transfected with M-fl, transfected
with M-fl and blocked with α9β1 antibody, treated with
recombinant uPAR or treated with recombinant uPAR
and blocked with α9β1 antibody. 48–72 hrs after transfec-
tion or 1–2 hrs after recombinant uPAR treatment, cells
were treated with 50 mM EDTA, washed with PBS,pelleted at 1000 rpm for 5 min, and re-suspended in PBS
in an appendorff tube at a concentration of 1 × 106 cells/
mL. Cells were then incubated with HRP-conjugated
iNOS antibody for 1 hr on ice, pelleted, and washed three
times with PBS to remove excess primary antibody. Cells
were then re-suspended in 1 ml of PBS and incubated with
Alexa Fluor® 594 (goat anti-mouse IgG, red) fluorescent
labeled secondary antibody for 1 hr on ice. After three
more washes in PBS, cell pellet was re-suspended in 10%
buffered formalin and analyzed on a Coulter EPICS XL
AB6064 flow cytometer (Beckman Coulter, Fullerton, CA).Detection of NO in 5310 glioma cells
DAF-2DA is a non-fluorescent cell permeable reagent that
can measure free NO in living cells. Once inside the cell,
the diacetate groups of the DAF-2DA reagent are hydro-
lyzed by cytosolic esterases, thus releasing DAF-2 and se-
questering the reagent inside the cell. Production of NO in
the cell, if any, converts the non-fluorescent dye, DAF-2, to
its fluorescent triazole derivative, DAF-2 T. 5310 glioma
xenograft cells cultured in 12-well plates were transfected
with MMP-9 or uPAR overexpressing plasmids (M-fl or U-
fl, respectively) or MU-sh plasmid shRNA. Seventy two
hours after transfection, a few wells containing M-fl or U-fl
transfected 5310 cells were treated with L-NAME (1 mM).
In order to demonstrate that MMP-9 and uPAR-mediated
glioma cell migration utilizes nitric oxide, four hours after
treatment with L-NAME, 5310 glioma cells from all the
treatment groups including controls were treated with
DAF-2DA reagent and the cells were incubated for 60 min
at 37°C. To remove the excess dye and stain, the nucleus
for quantitative analysis, samples were washed with PBS
and resuspended in PBS containing DAPI. Green fluores-
cence and the respective DAPI images were captured by
using a fluorescent microscope.Densitometry
Densitometry was performed using Image J Software
(National Institutes of Health) to quantify the band in-
tensities obtained from Western blot analysis. Data rep-
resent average values from three separate experiments.Statistical analysis
Statistical comparisons were performed using Graph Pad
Prism software (version 3.02). Quantitative data from
Western blot analysis, wound healing assay, spheroid mi-
gration assay and matrigel invasion assays were evaluated
for statistical significance using one-way ANOVA. Bonfer-
roni’s post hoc test (multiple comparison tests) was used to
compare any statistical significance between groups. Differ-
ences in the values were considered significant at p < 0.05.
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Effect of inhibition of iNOS on cell migration and invasion
Recently, it was reported that treatment with NO donor,
sodium nitroprusside significantly induced motility of gli-
oma cell lines [17]. In addition application of the iNOS in-
hibitor, L-NAME, to these glioma cell lines impaired their
movement. In the present study, prominent and signifi-
cant reduction in wound healing (indicative of decreased
migration potential) was noticed in L-NAME-treatedFigure 1 Migration potential of U251 glioma cells reduced after treat
six-well plates and transfected with full-length MMP-9 (M-fl) and uPAR (U-fl) p
wells with a 200 μL pipette tip. This point was considered to be the 0 hr, and
point, additional wells of a six-well plate containing U251 cells from control, M
inhibitor of iNOS at 1 mM concentration. At the 21st hr, the cells were checke
graph represents the quantification of wound healing assay results. Columns
(Ctrl). #p < 0.05 vs. M-fl. ##p < 0.05 vs. U-fl. (b) U251 spheroids were transfected
treated with L-NAME. Bar graph represents the quantification of cell migration
represent ± SEM. *p < 0.05 vs. M-fl. #p < 0.05 vs. U-fl.control, M-fl-, and U-fl- transfected U251 glioma cells as
compared to untreated cells from the respective groups
(Figure 1a). In addition, our results have clearly demon-
strated that the wound healing significantly increased
(indicative of increased cell migration) in M-fl- and U-
fl- transfected U251 glioma cells as compared to control
U251 cells. This is in agreement with our earlier report
wherein we showed an increased cell migration of 5310
human glioma xenograft cells after MMP-9 or uPARment with iNOS inhibitor. (a) U251 glioma cells were cultured in
lasmids. 72 hrs after transfection, a straight scratch was made in individual
the width of the wound was photographed under a microscope. At this
-fl and U-fl treatments were subjected to treatment with L-NAME, an
d for wound healing and again photographed under a microscope. Bar
represent mean (n = 3). Error bars represent ± SEM. *p < 0.05 vs. control
with M-fl and U-fl plasmids. A few spheroids from each group were
from the spheroids. Columns represent mean (n = 3). Error bars
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assessed the effect of iNOS inhibition on MMP-9- or
uPAR-mediated glioma cell migration in U251 cells by
spheroid migration assay. We noticed a significant reduc-
tion in the migration potential of M-fl- or U-fl- transfected
U251 cells from their spheroids after treatment with L-
NAME (Figure 1b). These results have clearly demon-
strated the involvement of iNOS in the cell migration
mediated by MMP-9 or uPAR in glioma cells. As expected,
we noticed an increased invasion potential of both U251
glioma cells and 5310 glioma xenografts after transfection
with M-fl and U-fl overexpression plasmids (Figure 2a). L-
NAME treatment prominently and significantly reduced
the invasion potential of untreated and M-fl- or U-fl-Figure 2 Matrigel invasion assay of glioma cells and immunohistochem
assay of U251 and 5310 cells transfected with full-length MMP-9 (M-fl), and uP
invasion was calculated from the mean of the average number of invaded
mean (n = 3). Error bars represent ± SEM. *p < 0.05 vs. control. #p < 0.05 vs
for immunohistochemical analysis followed by DAB staining to determinetransfected U251 and 5310 cells (Figure 2b). In the present
study, reduced invasion potential of untreated glioma cells
after L-NAME treatment was also attributed to MMP-9
and uPAR involvement because simultaneous knockdown
of MMP-9 and uPAR in glioma xenograft cells significantly
reduced their invasion potential compared to untreated gli-
oma cells [8].
Inducible nitric oxide synthase expression in glioma
Endogenous NO exhibits pleotropic roles within cancer
cells and tumors, and studies employing inhibition or gen-
etic deletion of endogenous NO synthases (NOSs) support
a tumor-promoting role for NO [18,19]. We noticed prom-
inent iNOS protein expression in clinical GBM samplesical analysis of glioblastoma clinical samples. (a) Matrigel invasion
AR (U-fl) plasmids and treated with or without L-NAME. (b) Percent
cells obtained from three separate experiments. Columns represent
. M-fl. ##p < 0.05 vs. U-fl. (c) GBM tissue microarrays were processed
the presence of iNOS.
Figure 3 Effect of various treatments on iNOS expression in glioma cells in vitro and in vivo. (a) U251 and 5310 cells were transfected with
scrambled vector (SV-sh), MMP-9 plasmid shRNA (M-sh), uPAR plasmid shRNA (U-sh), or MMP-9 + uPAR plasmid shRNA (MU-sh) and then
subjected to immunocytochemical analysis for iNOS expression. (b) Immunohistochemical comparison of the iNOS expression in control,
M-sh-, U-sh- and MU-sh-treated nude mice that were pre-injected (intracerebrally) with 5310 cells (0.2 × 106 cells). (c) RT-PCR analysis of U251 and
5310 cells transfected with full-length MMP-9 (M-fl), and uPAR (U-fl) plasmids to evaluate the changes in iNOS mRNA expression.
Figure 4 Western blot analysis of U251 and 5310 glioma cells subjected to various treatments. (a) Western blot analysis showing the effect
of transfections with scrambled vector (SV-sh), MMP-9 plasmid shRNA (M-sh), uPAR plasmid shRNA (U-sh), or MMP-9 + uPAR plasmid shRNA (MU-sh) on
the expression levels of several proteins associated with α9β1-mediated cell migration in U251 and 5310 glioma cells (n = 3). (b) Quantification of
Western blot analysis results using Image J software. Columns represent mean (n = 3). Error bars represent ± SEM. *p < 0.05 vs. control.
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in U251 and 5310 human glioma cells that were utilized in
the present study (Figure 3a). High iNOS expression corre-
lates with decreased survival in human glioma patients, and
iNOS inhibition slows glioma growth in animal models
[20]. MMP-9 or uPAR knockdown by shRNA-mediated
gene silencing reduced iNOS protein expression in U251
and 5310 glioma cells. Reduction of iNOS expression was
prominent when these cells were simultaneously downreg-
ulated with both MMP-9 and uPAR compared to their indi-
vidual knockdowns (Figure 3a). Alternatively, it is also
possible that the NO generated from iNOS activation can
regulate both the expression of MMP-9 and its activation
through cGMP dependent or independent mechanisms
[11,12,21]. As expected, iNOS protein expression was no-
ticed in gliomas obtained after intracranial implantation
of 5310 cells in nude mice. However, these glioma cells-
implanted nude mice showed reduced iNOS expressionFigure 5 FACS analysis and Western blot analysis. (a) FACS analysis wa
expression in U251 glioma cells and 5310 glioma xenografts. (b) Western b
expression in U251 and 5310 cells. (c) Quantification of Western blot analys
Error bars represent ± SEM. *p < 0.05 vs. control.after treatments with M-sh, U-sh or MU-sh (Figure 3b).
Recently, we have reported a significant reduction of intra-
cranial tumor growth in these nude mice after M-sh, U-sh
or MU-sh treatments [8,22]. Increased iNOS mRNA ex-
pression in MMP-9 or uPAR overexpressed glioma cells
further demonstrated the interaction between MMP-9/
uPAR and iNOS (Figure 3c).
Interactions among MMP-9/uPAR, α9β1 integrin and iNOS
in glioma cells
Our recent studies clearly demonstrated the role played by
α9β1 integrin in MMP-9-/uPAR-mediated glioma cell mi-
gration [8,23]. α9β1 integrin ligation can activate signaling
through Src and FAK-mediated tyrosine phosphorylation of
multiple proteins including p130Cas and paxillin [24,25]. In
agreement with these reports, protein expression of several
molecules [cSRC, pSRC (Tyr416), p130Cas] associated with
α9β1-mediated cell migration were significantly affecteds performed to evaluate the effect of various treatments on iNOS
lot analysis showing the effect of various treatments on iNOS protein
is results using Image J software. Columns represent mean (n = 3).
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5310 cells (Figure 4a & 4b). Src activation was a proximal
and dominant signaling regulating α9β1-mediated cell
migration [25]. However, the molecular details of α9β1-
induced Src activation remain to be elucidated. It could
be possible that Src may directly interact with the cyto-
plasmic tail of α9, subsequently recruiting other signal-
ing proteins to form an associated multimeric signaling
complex which can activate iNOS. Recently it was shown
that integrin α9β1 regulates iNOS activity via Src tyrosine
kinase, resulting in increased NO production and NO-
induced cell migration [25]. FACS analysis demonstrated
that the overexpression of MMP-9 by transfection with
MMP-9 overexpressing plasmid or treatment with recom-
binant uPAR in both U251 and 5310 glioma cells in-
creased iNOS expression (Figure 5a). The increased iNOS
expression in these cells has been reverted with α9β1 in-
tegrin blockade, indicating that MMP-9 or uPAR regulates
iNOS via α9β1 integrin. Although the α9β1 integrin block-
ade in recombinant uPAR treated 5310 glioma cells did
not prominently effect the iNOS expression, blockade of
iNOS expression by L-NAME in uPAR overexpressed
5310 cells significantly reduced their invasion potential
(Figure 5a & 2b). Further, α9β1 integrin blockade in uPAR
overexpressed 5310 glioma cells significantly reduced their
migration potential [8]. As expected, protein expression
of iNOS was significantly increased upon MMP-9/uPAR
overexpression in these glioma cells (Figure 5b & 5c). In
addition to the reduced cell migration after L-NAME
treatment in MMP-9 or uPAR overexpressed U251 glioma
cells in the present study, increased NO production inFigure 6 Fluorescence microscopy of the DAF-2DA-loaded 5310 cells
green fluorescence after transfection of 5310 glioma cells with full-length M
(MU-sh) followed by DAF-2DA treatment. Separate groups 5310 of cells tra
inhibitor of iNOS at 1 mM concentration prior to DAF-2DA treatment. Bar g
cells after various treatments (n = 3). Error bars represent ± SEM. *p < 0.05MMP-9 or uPAR overexpressed glioma cells and the asso-
ciated reduction in NO levels in those cells after L-NAME
treatment clearly demonstrated the possible involvement
of NO in MMP-9 or uPAR- regulated glioma cell migra-
tion (Figure 6). NO production was reduced in MMP-9
and uPAR knockdown 5310 glioma cells compared to
controls (Figure 6). In the present study, although the re-
duced NO levels in MMP-9 and uPAR knockdown glioma
cells are not significant compared to controls, the reduction
in NO levels could be sufficient to significantly reduce gli-
oma cell migration. These results allowed us to attribute
the involvement of iNOS pathway in addition to other
demonstrated pathways to the reduced glioma cell migra-
tion after MMP-9 and uPAR shRNA-mediated gene silen-
cing that was demonstrated earlier [8].
Activation of iNOS can promote cancer cell migration
via multiple mechanisms. NO generated from iNOS acti-
vation can act as a co-factor to GC to promote synthesis
of the second messenger cGMP, which regulates cell mi-
gration in both a PKG dependent and independent fash-
ion [11,12]. Relevant to integrin function, NO released
into the cellular microenvironment can impact the as-
sembly of focal adhesions. NO-induced delay of focal ad-
hesion assembly or their premature de-stabilization has
significant effects on cell migratory responses. Further,
the reduced NO levels after inhibition of iNOS by genetic
and pharmacological approaches impede glial cell pro-
liferation, invasiveness, and tumor growth in vivo [26].
A previous study demonstrated that the natural products
with anti-inflammatory effects such as wogonin and quer-
cetin inhibited MMP-9 activity, iNOS expression and NOsubjected to various treatments. Representative images showing
MP-9 (M-fl) or uPAR (U-fl) plasmids, or MMP-9 + uPAR plasmid shRNA
nsfected with M-fl or U-fl were treated for 4 hours with L-NAME, an
raph represents the quantification of DAF-2 T positive 5310 glioma
vs. control. #p < 0.05 vs. M-fl. ##p < 0.05 vs. U-fl.
Figure 7 Schematic representation of MMP-9- and/or uPAR-mediated glioma cell migration that utilizes the α9β1-iNOS pathway. In
glioma cells, uPAR and MMP-9 upregulate iNOS levels via their interactions with α9β1 integrin, which contributes to glioma cell migration. MU-sh
treatment reduced α9β1 integrin levels and, in turn, reduced iNOS, an enzyme that produces NO.
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http://www.biomedcentral.com/1471-2407/13/590production in rat glioma C6 cells [27]. The reduced gli-
oma cell migration in the present study after MMP-9 and/
or uPAR knockdown is possibly attributed to the regula-
tion of iNOS pathway via α9β1 integrin which are down-
stream to both MMP-9 and uPAR (Figure 7).Conclusions
MMP-9/uPAR overexpression enhanced the potential of
glioma cell migration and invasion. L-NAME, an inhibitor
of iNOS, inhibited MMP-9-/uPAR-induced glioma cell
migration and invasion. iNOS expression was associated
with GBM. MMP-9/uPAR overexpression increased iNOS
expression and vice versa. MMP-9 and/or uPAR downreg-
ulation reduced the protein expression levels of several
molecules associated with the α9β1-iNOS pathway medi-
ated cell migration. In summary, glioma cells expressing
MMP-9 and/or uPAR utilize α9β1-iNOS pathway to medi-
ate cell migration.
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